ArticleRSC advances2023
Improved intracellular delivery of exosomes by surface modification with fluorinated peptide dendrimers for promoting angiogenesis and migration of HUVECs.
Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Encapsulation and assessment of therapeutic cargo in engineered exosomes: a systematic review.Journal of nanobiotechnology · 2024Pooled it
- Multifunctional Engineering of Exosomes for Precision Therapeutics: Strategies for Targeted Delivery, Barrier Evasion, and Clinical Translation.Pharmaceutical research · 2025Review
- Progress of research on engineered extracellular vesicles from different sources for disease treatment.Histology and histopathology · 2025Review
- Engineering exosomes for liver disease: a new insight in regenerative medicine and drug delivery.Applied biochemistry and biotechnology · 2025Review
- Cartilage-targeting exosomes for delivery of receptor antagonist of interleukin-1 in osteoarthritis treatment.Osteoarthritis and cartilage · 2025Article
- Methods and Challenges in Purifying Drug-Loaded Extracellular Vesicles.Journal of extracellular vesicles · 2025Review
- Beneficial and challenges of exosome application in ischemic heart disease.Stem cell research & therapy · 2025Review
- Methods, Mechanisms, and Application Prospects for Enhancing Extracellular Vesicle Uptake.Current medical science · 2024Review
- Extracellular Vesicles and Hydrogels: An Innovative Approach to Tissue Regeneration.ACS omega · 2024Review
- Review
- New Gene Markers of Exosomal Regulation Are Involved in Porcine Granulosa Cell Adhesion, Migration, and Proliferation.International journal of molecular sciences · 2023Article
- Advances in Therapeutic Applications of Extracellular Vesicles.International journal of nanomedicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes exhibit great potential as novel therapeutics for tissue regeneration, including cell migration and angiogenesis. However, the limited intracellular delivery efficiency of exosomes might reduce their biological effects. Here, exosomes secreted by adipose-derived mesenchymal stem cells were recombined with fluorinated peptide dendrimers (FPG3) to form the fluorine-engineered exosomes (exo@FPG3), which was intended to promote the cytosolic release and the biological function of exosomes. The mass ratio of FPG3 to exosomes at 5 was used to investigate its cellular uptake efficiency and bioactivity in HUVECs, as the charge of exo@FPG3 tended to be stable even more FPG3 was applied. It was found that exo@FPG3 could enter HUVECs through a variety of pathways, in which the clathrin-mediated endocytosis played an important role. Compared with exosomes modified with peptide dendrimers (exo@PG3) and exosomes alone, the cellular uptake efficiency of exo@FPG3 was significantly increased. Moreover, exo@FPG3 significantly enhanced the angiogenesis and migration of HUVECs
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.